Close Menu
Home » Illumina Sues Premaitha Health Over NIPT IP; Swiss Firm Adopts Premaitha's Iona CE-IVD Test

Illumina Sues Premaitha Health Over NIPT IP; Swiss Firm Adopts Premaitha's Iona CE-IVD Test

Mar 16, 2015
|
staff reporter

NEW YORK (GenomeWeb) – Illumina and its wholly-owned subsidiary Verinata Health have filed a patent infringement suit against Premaitha Health over IP relating to non-invasive prenatal testing, the companies said today.

The suit, filed in the High Court of Justice, Chancery Division, Patents Court in the UK, asserts European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1, both relating to the use of cell-free fetal DNA for NIPT.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Snakes and Bats and People

An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.

Coyote Match in Chicago

DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.

Viruses on Ice

An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.

Nature Papers Examine Ancient Human DNA From Africa, Present Approach to Study Microbiota

In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.

What's Popular?

In Business News

  1. 23andMe Lays off 100 Employees Across Consumer Business

  2. 10x Genomics Lawsuit Over Exclusivity of Harvard Single-Cell IP License Going to Trial

  3. Quest Diagnostics Acquires Blueprint Genetics

  4. Abbott Q4 Diagnostics Revenues up 5 Percent, MDx Revenues Decline

  5. Adaptive Biotechnologies Announces Preliminary FY19 Revenue Increase, $257M Stock Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.